Nanoparticle Applications in Cardiovascular Disease Management

Nanoparticles offer transformative solutions to the long-standing challenges of cardiovascular disease management by enabling highly controlled drug delivery, enhanced imaging sensitivity and precision targeting of pathological sites. In atherosclerosis, nanocarriers can preferentially accumulate in plaques via enhanced permeability, delivering anti-inflammatory agents or cholesterol-efflux stimulators directly to macrophages while minimising systemic exposure. In acute myocardial infarction, nanoparticle-mediated delivery of cardioprotective agents at reperfusion has shown superior myocardial salvage compared with free drugs. Beyond therapy, engineered nanoparticles—ranging from lipid-based formulations to inorganic cores—serve as contrast enhancers for magnetic resonance, fluorescence and radionuclide imaging, improving detection of vulnerable plaques and monitoring of treatment response. Recent advances in nano-enabled biomaterials have also been applied to cardiac tissue engineering, where incorporation of nanostructures can modulate mechanical properties, electrical conductivity and immune interactions within grafts. Ex vivo diagnostic platforms utilising nanoparticle-enhanced sensors are beginning to deliver rapid, ultrasensitive assays for biomarker quantification. Collectively, these approaches illustrate the global potential of nanomedicine to refine diagnostics, reduce adverse effects and personalise therapy across the spectrum of cardiovascular conditions.

Research from Nature Portfolio

Recent studies have mapped the landscape of cardiovascular nanomedicine, categorising applications into three broad areas: cardiac biomaterials, vasculature-targeted therapeutics and ex vivo diagnostics. Cardiac scaffolds incorporating nanomaterials have been shown to improve electrical integration and modulate post-infarction inflammation. Systemic nanoformulations engineered for selective vascular targeting combine ligand-mediated active binding with passive accumulation in inflamed or ischaemic tissue, enhancing delivery of anti-inflammatory and lipid-modulating agents. Parallel efforts in immunoimaging exploit nanoparticle probes that bind immune cell subsets, offering real-time visualisation of inflammatory progression. Moreover, nano-enabled point-of-care devices demonstrate heightened sensitivity for low-abundance cardiac biomarkers, promising rapid screening in decentralised settings. These integrated strategies underscore the imminent translation of nanotechnologies into clinical trials and practice.

Nanoparticle Applications in Cardiovascular Disease Management publication trend

The graph below shows the total number of articles in nanoparticle applications in cardiovascular disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle: A submicrometre particle (1–100 nm) with tunable surface and core properties used for targeted delivery or imaging in medical applications.

Theranostics: A combined diagnostic and therapeutic approach in which a single agent or platform both visualises disease and administers treatment.

Atherosclerosis: A chronic vascular condition characterised by lipid-rich plaque formation in arterial walls, leading to stenosis or rupture.

Macrophage: A type of immune cell involved in inflammation and plaque development that can internalise nanoparticles for targeted therapy.

Ischaemia-reperfusion injury: Tissue damage caused by restoration of blood flow after a period of ischaemia, often mitigated by nanoparticle-mediated drug delivery.

References

1. Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease. Cardiovascular Research (2024).
2. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model. PLOS ONE (2015).
3. Nanomedicines for cardiovascular disease. Nature Cardiovascular Research (2023).
4. Nanomaterials as Novel Cardiovascular Theranostics. Pharmaceutics (2021).